Provectus announced that the company has successfully developed and manufactured a second halogenated xanthene (HX), adding to its lead, clinical-stage, HX small molecule called rose bengal sodium (RBS). The molecular name of the newly synthesized HX is 4,5,6,7-tetrabromo-3',6'-dihydroxy-2',4',5',7'-tetraiodo-3H-spiro[isobenz- ofuran-1,9'-xanthen]-3-one. Provectus' intellectual property estate comprises an entire class of proprietary, related HX molecules that are proprietarily-synthesized using Quality-by-Design principles (QbD) under current Good Manufacturing Practice (cGMP) and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1985 USD | +1.07% | +1.90% | +106.77% |
1st Jan change | Capi. | |
---|---|---|
+106.77% | 83.28M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.70% | 22.15B | |
-17.37% | 21.02B | |
-8.40% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- PVCT Stock
- News Provectus Biopharmaceuticals, Inc.
- Provectus Biopharmaceuticals Announces Synthesis of New Halogenated Xanthene Small Molecule